What Peptides Actually Are — and What They Aren’t

The word “peptide” has become a marketing category. It is used interchangeably with steroids, hormone optimization, anti-aging supplements, recovery tools, and weight loss drugs in ways that obscure rather than clarify what these molecules actually are. If you are considering peptide therapy or trying to understand what your physician is prescribing, getting the basic vocabulary right matters more than people realize.

This is a primer on what peptides are, what they are not, and why the distinction has practical implications for how to think about peptide therapy.

The basic definition

A peptide is a short chain of amino acids — the same building blocks that make up proteins. The technical distinction between a peptide and a protein is somewhat arbitrary and based on length: peptides are typically defined as chains of fewer than 50 amino acids, while proteins are longer chains. Some references use 100 amino acids as the cutoff. The chemistry is identical; only the size differs.

This means peptides are fundamentally different from steroids, which are derived from cholesterol and have a four-ring carbon structure. Testosterone, estradiol, cortisol, and synthetic anabolic steroids are all steroids. They are not peptides, and they work through entirely different cellular mechanisms.

Peptides are also distinct from supplements. Supplements typically deliver vitamins, minerals, herbal extracts, or other compounds that supplement the diet. Peptides are signaling molecules that interact with specific cellular receptors to produce specific biological effects. The regulatory framework, the manufacturing standards, and the mechanism of action are all different.

What peptides do in the body

The body produces hundreds of endogenous peptides as signaling molecules. Insulin is a peptide. So is glucagon, growth hormone-releasing hormone, oxytocin, vasopressin, and the natriuretic peptides produced by the heart. These molecules carry information between cells and organ systems, regulating everything from glucose metabolism to fluid balance to social bonding.

Therapeutic peptides typically work in one of three ways. Some are exact synthetic copies of endogenous peptides, used to replace deficient signaling — recombinant insulin for diabetes is the classic example. Others are modified versions of endogenous peptides, engineered to have longer half-lives or more selective effects than the natural molecule — semaglutide is a modified GLP-1 with structural changes that extend its duration from minutes to a week. Still others are entirely synthetic peptides discovered or designed to bind specific receptors with effects that may or may not parallel natural signaling.

The shared feature is targeted action through receptor binding. A peptide that binds the GLP-1 receptor produces specific effects on insulin secretion, gastric emptying, and central appetite. A peptide that binds melanocortin receptors produces specific effects on pigmentation, sexual response, or inflammation depending on which receptor subtype is engaged. This receptor-mediated specificity is what distinguishes peptide therapy from broader interventions.

What peptides are not

Peptides are not anabolic steroids. Steroids work by binding intracellular androgen or estrogen receptors and modulating gene transcription related to protein synthesis. Peptides operate through cell surface receptors and intracellular signaling cascades that are biochemically distinct. There are peptides that affect muscle growth (growth hormone secretagogues, for example), but the mechanism, side effect profile, and regulatory category differ substantially from steroids.

Peptides are not “natural” supplements in any meaningful sense. The marketing language sometimes implies that because peptides are based on natural biological signaling, they are gentler or safer than other pharmaceuticals. This is not accurate. A potent GLP-1 agonist is a powerful pharmacological intervention regardless of its biological origin. Side effects, contraindications, and need for medical supervision apply to peptides the same way they apply to any other prescription pharmaceutical.

Peptides are not all the same regulatory category. This is the source of some of the most important confusion. Some peptides are FDA-approved pharmaceuticals manufactured by major drug companies (semaglutide, tirzepatide, oxytocin, leuprolide, dozens of others). Some are dispensed by licensed compounding pharmacies under specific regulatory frameworks (BPC-157, sermorelin, ipamorelin, others). Some are sold in research-only contexts and are not legally available for human use. The regulatory category has substantial implications for quality control, prescribing legitimacy, and what the patient is actually receiving.

Why size and structure matter

Peptide pharmacology has practical features that follow from the molecular structure. Most peptides have very short half-lives in the body — measured in minutes — because the same enzymes that break down dietary protein break down circulating peptides. This is why most therapeutic peptides require frequent dosing, structural modifications to extend duration, or specialized formulations.

Most peptides cannot be taken orally because gastric acid and digestive enzymes destroy them before absorption. The exceptions — like oral semaglutide, which uses a special absorption-enhancer formulation — required substantial pharmaceutical engineering to overcome this barrier. Most peptide therapy is therefore administered by subcutaneous injection, intranasal spray, or other routes that bypass the digestive tract.

Peptides generally do not cross the blood-brain barrier well. This is a feature when central effects are not desired but a limitation when they are. Intranasal administration of certain peptides (Selank, Semax, oxytocin) is one strategy for delivering small amounts directly to the central nervous system through the olfactory mucosa, bypassing the blood-brain barrier limitations.

The therapeutic landscape today

Peptide therapy spans a wide spectrum of clinical applications and evidence bases. At one end are decades-old, FDA-approved, multibillion-dollar drug categories: insulin, GLP-1 agonists, GnRH analogs, calcitonin, somatostatin analogs, and the new generation of incretin therapies that are reshaping metabolic medicine. The evidence for these is robust, the regulatory framework is clear, and prescribing practices are well-established.

In the middle are compounded peptides with substantial preclinical evidence and accumulated practitioner experience but limited Western RCT validation — BPC-157, TB-500, sermorelin and CJC-1295 in the GH-axis space, thymosin alpha-1, and others. These occupy a legitimate clinical role for many practitioners but require honest evidence-based conversations with patients about what is and is not known.

At the other end are research peptides without established clinical pathways — compounds being studied in laboratories but not yet developed to the point where outpatient clinical use is appropriate. These are sometimes promoted in consumer-facing channels in ways that get ahead of the actual evidence.

Why so many peptides have weaker evidence than you would expect

One pattern that surprises patients new to the peptide field is how many compounds with strong mechanistic rationale and decades of research history lack the kind of large randomized trials typically used for FDA approval. The reason is largely economic rather than scientific.

Bringing a drug through Phase III trials and FDA approval typically costs hundreds of millions of dollars. Drug companies undertake this investment because patent protection on novel chemical entities allows them to recover the investment through marketing exclusivity. Most of the peptides in clinical use that fall outside this commercial framework — peptides that are fragments of natural proteins, peptides whose patent protection has expired, peptides where the chemistry does not support strong patent claims — do not attract this level of investment.

The result is a category of compounds where the mechanistic story is well-developed, the preclinical evidence may be substantial, the safety profile is reasonable in clinical use, and the gold-standard human RCT validation is structurally unlikely to occur. This is not a problem unique to peptides — many established medical interventions have similar evidence patterns — but it is particularly pronounced in the peptide field. Honest practitioners acknowledge this rather than pretending the evidence is more robust than it is.

What this means for you

If you are considering peptide therapy, the most useful first step is understanding what specifically is being prescribed and where it falls on this spectrum. A reasonable clinical conversation will address the regulatory category (FDA-approved, compounded, or research), the specific evidence base for your indication, the realistic expectations about effect size and timeline, the side effects and contraindications, and what response should look like.

Be skeptical of clinicians who present peptide therapy as a unified category with similar evidence and similar use cases across all peptides. The reality is more nuanced. Semaglutide has Phase III cardiovascular outcomes data. BPC-157 does not. Both can be appropriate clinical choices in the right context, but the conversations about each should look different.

The peptide field is genuinely interesting. It also attracts marketing claims that move faster than evidence. Understanding what these molecules actually are — chemically, biologically, and regulatorily — gives you the foundation to evaluate specific recommendations and ask better questions about your own care.